**Template Data Table. Selected Clinical Trial Experience (*use filename Clinical Trial Experience*). LIMITED to FIVE PAGES.**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| CT ID1 | Study Title | Intervention/ Treatment/ Diagnostic | Trial Phase2 | Single or Multi-site3 | Primary Site Institution (as listed in eRA) | Primary Site eRA Commons Institutional Profile No. | Primary Site Institution EIN or DUNS Number | Funding Source4 | Months from Actual Start/ Completion Date | Actual Cumulative Enrollment | Primary Endpoint Result Indication |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |

Include all NIH–funded single and multi-site clinical trials with site activation during the 6 months up to and prior to the application from the hub and participating partners and collaborators. Enumerate total actual cumulative accrual for each clinical trial described. Include an overall impact statement for each clinical trial and study and reference to any PMID or abstract (include year)

1CT ID: Clinical Trial Identifier: Enter NIH eRA Human Subjects System (HSS) ID or ClinicalTrials.gov Identifier [National Clinical Trial (NCT) ID]. Enter Local Trial ID if neither HSS nor NCT are applicable.

2Enter Phase or N/A

Phase

**Early Phase I:** Exploratory trials, involving very limited human exposure, with no therapeutic. or diagnostic intent (e.g., screening studies, microdose studies). See FDA guidance on exploratory IND studies for more information.

**I:** Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.

**I/II:** Trials that are a combination of phases 1 and 2.

**II:** Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

**II/III:** Trials that are a combination of phases 2 and 3.

**III:** Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

**IV:** Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.

**N/A:** Trials without phases (for example, studies of devices or behavioral interventions).

3Single site: enter 1. Multi-site: enter total number of participating sites.

4Enter institutional, grant, contract, and/or non-profit.